{"id":471633,"date":"2021-04-06T08:33:23","date_gmt":"2021-04-06T12:33:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471633"},"modified":"2021-04-06T08:33:23","modified_gmt":"2021-04-06T12:33:23","slug":"new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/","title":{"rendered":"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress"},"content":{"rendered":"
\n

BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will deliver a poster presentation titled \u201cPharmacokinetics of an Oral Human Growth Hormone (hGH) Formulation in Rats and Mice\u201d at the 31st<\/sup> Annual European Pharma Congress in London on April 28-29, 2021.<\/p>\n

Prescription human growth hormone (hGH), a widely used therapeutic molecule, is currently only administered via subcutaneous injection for the treatment of growth hormone deficiency as well as other indications. Therapeutic hGH was a $3.7<\/a> billion market in 2020 and is expected to grow to $8.5 billion by 2027. Also known as somatotropin, therapeutic hGH is different from oral over-the-counter supplements which claim to increase the body\u2019s own production of hGH.<\/p>\n

In a preclinical study, Entera\u2019s hGH formulation was administered orally to mice and rats. Plasma samples analyzed showed substantial gastrointestinal absorption of the oral hGH formulation and significant systemic exposure to the drug.<\/p>\n

\u201cOur proprietary oral protein delivery platform continues to present expanding therapeutic applications and corresponding market opportunities. An oral hGH may offer numerous advantages including greater patient compliance, reduced pain, longer shelf life, no injection site reactions, and lower immunogenicity,\u201d stated Entera CEO Spiros Jamas. \u201cWe are pleased to have our abstract accepted by the European Pharma Congress and look forward to presenting the data.\u201d<\/p>\n

\n About Entera Bio<\/strong>\n <\/p>\n

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company\u2019s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company\u2019s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com<\/a>.<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

Various statements in this release are \u201cforward-looking statements\u201d under the securities laws. Words such as, but not limited to, \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cdesign,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cobjective,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwill,\u201d and \u201cwould,\u201d or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.<\/p>\n

Important factors that could cause actual results to differ materially from those reflected in Entera\u2019s forward-looking statements include, among others: changes in our interpretation of the complete3-month biomarker data from the ongoing Phase 2 clinical trial of EB613, the timing of data readouts from the ongoing Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613, which is still ongoing and our analysis of those full results, the FDA\u2019s interpretation and review of our results from and analysis of our Phase 2 trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; a possible suspension of the Phase 2 clinical trial of EB613 for clinical or data-related reasons; the impact of COVID-19 on Entera\u2019s business operations including the ability to collect the necessary data from the Phase 2 trial of EB613; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay-offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera\u2019s agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID-19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the ongoing Phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera\u2019s other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the scope, progress and costs of developing Entera\u2019s product candidates including EB612 and GLP-2; Entera\u2019s reliance on third parties to conduct its clinical trials; Entera\u2019s expectations regarding licensing, business transactions and strategic collaborations; Entera\u2019s operation as a development stage company with limited operating history; Entera\u2019s ability to continue as a going concern absent access to sources of liquidity; Entera\u2019s expectations regarding its expenses, revenue, cash resources, liquidity and financial condition; Entera\u2019s ability to raise additional capital; Entera\u2019s interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera\u2019s ability to obtain and maintain regulatory approval for any of its product candidates; Entera\u2019s ability to comply with Nasdaq\u2019s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera\u2019s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the \u201cSpecial Note Regarding Forward-Looking Statements,\u201d \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of Entera\u2019s annual and current filings which are on file with the SEC and available free of charge on the SEC\u2019s website at http:\/\/www.sec.gov. Additional factors may be set forth in those sections of Entera\u2019s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and in Entera\u2019s annual report on Form 20-F and current reports on Form 6-K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera\u2019s results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.<\/p>\n

All written and verbal forward-looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n


\n
\n \n <\/div>\n

\n
Contact:\r\n\r\nSpiros Jamas, CEO\r\nTel: +001 617-362-3579\r\nspiros@enterabio.com\u00a0<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will deliver a poster presentation titled \u201cPharmacokinetics of an Oral Human Growth Hormone (hGH) Formulation in Rats and Mice\u201d at the 31st Annual European Pharma Congress in London on April 28-29, 2021. Prescription human growth hormone (hGH), a widely used therapeutic molecule, is currently only administered via subcutaneous injection for the treatment of growth hormone deficiency as well as other indications. Therapeutic hGH was a $3.7 billion market in 2020 and is expected to grow to $8.5 billion by 2027. Also known as somatotropin, therapeutic hGH is different from oral over-the-counter … <\/p>\n
Continue reading “New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-471633","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNew Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will deliver a poster presentation titled \u201cPharmacokinetics of an Oral Human Growth Hormone (hGH) Formulation in Rats and Mice\u201d at the 31st Annual European Pharma Congress in London on April 28-29, 2021. Prescription human growth hormone (hGH), a widely used therapeutic molecule, is currently only administered via subcutaneous injection for the treatment of growth hormone deficiency as well as other indications. Therapeutic hGH was a $3.7 billion market in 2020 and is expected to grow to $8.5 billion by 2027. Also known as somatotropin, therapeutic hGH is different from oral over-the-counter … Continue reading "New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-06T12:33:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress\",\"datePublished\":\"2021-04-06T12:33:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/\"},\"wordCount\":1299,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/\",\"name\":\"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI=\",\"datePublished\":\"2021-04-06T12:33:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/","og_locale":"en_US","og_type":"article","og_title":"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress - Market Newsdesk","og_description":"BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will deliver a poster presentation titled \u201cPharmacokinetics of an Oral Human Growth Hormone (hGH) Formulation in Rats and Mice\u201d at the 31st Annual European Pharma Congress in London on April 28-29, 2021. Prescription human growth hormone (hGH), a widely used therapeutic molecule, is currently only administered via subcutaneous injection for the treatment of growth hormone deficiency as well as other indications. Therapeutic hGH was a $3.7 billion market in 2020 and is expected to grow to $8.5 billion by 2027. Also known as somatotropin, therapeutic hGH is different from oral over-the-counter … Continue reading \"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-06T12:33:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress","datePublished":"2021-04-06T12:33:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/"},"wordCount":1299,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/","name":"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI=","datePublished":"2021-04-06T12:33:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTg1MSM0MTA2NDYzIzIwOTM3ODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-data-suggest-enteras-platform-orally-delivers-human-growth-hormone-study-results-to-be-presented-at-european-pharma-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"New Data Suggest Entera\u2019s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=471633"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471633\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=471633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=471633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=471633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}